Ipamorelin vs Sermorelin vs Tesamorelin: How to Choose the Right Growth Hormone Peptide

Choosing between ipamorelin, sermorelin, and tesamorelin is really a three-way trade-off between evidence depth, cost, and legal access — and the three peptides are not interchangeable substitutes. Two are growth-hormone-releasing hormone (GHRH) analogs; one is a ghrelin mimetic that works on a separate receptor entirely.

Tesamorelin has the strongest human data of the three — Phase 3 trial support and an FDA approval — but the narrowest indication and the highest price. Sermorelin is the established middle option, formerly FDA-approved and now legally compounded. Ipamorelin is the cheapest and, on independent testing platforms, the most-bought of the three, yet it has the least human outcome data. These growth hormone peptides all raise your body's own GH, so the right choice depends entirely on your goal — and on knowing what you are actually buying, because most ipamorelin and sermorelin sold online is unregulated research material.

What's the difference between ipamorelin, sermorelin, and tesamorelin?

Ipamorelin, sermorelin, and tesamorelin are three injectable peptides that raise growth hormone by prompting the pituitary to release more of its own GH, but they differ sharply in mechanism class, evidence quality, FDA status, and cost. Sermorelin and tesamorelin are GHRH analogs that act on the GHRH receptor, while ipamorelin is a selective ghrelin mimetic acting on a separate receptor. Tesamorelin is the only one with active FDA approval; sermorelin was formerly approved; ipamorelin was never approved. The right pick depends on your goal, not on which name you heard first.

The table below summarizes the three compounds at a glance. The rest of this article explains each row — the prose is where the real decision lives, not the table.

How do ipamorelin, sermorelin, and tesamorelin work?

The three peptides split into two mechanism classes, which is the single most important thing to understand before comparing them. Sermorelin (a 29-amino-acid GHRH fragment) and tesamorelin (a stabilized 44-amino-acid GHRH analog) bind the GHRH receptor on pituitary somatotrophs, mimicking the body's own growth-hormone-releasing hormone. Ipamorelin, a five-amino-acid ghrelin mimetic, binds the separate growth-hormone-secretagogue (GHS) receptor. Because they act on different receptors, a GHRH analog and ipamorelin are usually combined for a synergistic GH pulse rather than chosen as substitutes.

Sermorelin is GRF (1-29) — the first 29 amino acids of GHRH and the shortest fully functional fragment of the hormone. It stimulates a natural GH pulse but has a short half-life of roughly 10–20 minutes, so its action is potent but brief. As detailed in the sermorelin science guide, its biomimetic profile means somatostatin — the body's "off switch" for GH — continues to regulate output, making supraphysiological GH levels difficult to reach.

Tesamorelin is GHRH (1-44) with an N-terminal modification (a trans-3-hexenoyl group) that resists enzymatic breakdown, extending its half-life to roughly 26–38 minutes and giving it more sustained GH-releasing activity than sermorelin. That added stability, covered in the tesamorelin science guide, is the practical difference between the two GHRH analogs.

Ipamorelin works through a different door. It is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed by Novo Nordisk that activates the ghrelin receptor to trigger GH release. In the foundational preclinical study "Ipamorelin, the first selective growth hormone secretagogue" (Raun et al., 1998, European Journal of Endocrinology), ipamorelin released GH from rat pituitary cells with potency similar to GHRP-6 but — critically — did not raise ACTH or cortisol even at doses more than 200 times the GH-releasing dose. That selectivity, demonstrated in animal models, is the entire reason ipamorelin is preferred over older secretagogues. The ipamorelin science guide covers the receptor pharmacology in more depth. Because ipamorelin and a GHRH analog hit two different receptors, they are commonly paired — most often ipamorelin with CJC-1295, a longer-acting GHRH analog — to produce a larger combined GH pulse than either achieves alone.

What does the research actually show for each?

Evidence quality differs far more than marketing suggests, and it runs in the opposite direction to gray-market popularity. Tesamorelin has the strongest data — Phase 3 randomized controlled trials in HIV-associated lipodystrophy showing roughly 15% visceral-fat reduction, the basis for its FDA approval. Sermorelin has solid historical pediatric trial data behind its former Geref approval but thin modern randomized evidence for adult anti-aging use. Ipamorelin's foundational selectivity data is preclinical (animal models), with limited human outcome trials. In short, the compound with the least human evidence is the one most often bought.

Tesamorelin's pivotal trial, "Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV" (Falutz et al., 2007, NEJM), reported that visceral adipose tissue decreased by 15.2% in the tesamorelin group versus a 5.0% increase on placebo — a human RCT result. A subsequent "randomized placebo-controlled trial with a safety extension" (Falutz et al., 2010, J Acquir Immune Defic Syndr) confirmed durable visceral-fat loss without significant glucose perturbation. This is genuine Phase 3 human evidence, though it was conducted specifically in HIV-associated lipodystrophy, not in healthy adults seeking body composition or anti-aging effects.

Sermorelin's evidence sits in a middle tier. Its original FDA approval (Geref, 1997) rested on pediatric growth-hormone-deficiency trials — solid human data, but for diagnosis and childhood GHD, not adult optimization. In adults, the data is thinner and more modest. A controlled study in healthy elderly men, "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men" (Vittone et al., 1997, Metabolism), found that single nightly GHRH (1-29) — which is sermorelin — increased nocturnal GH release but produced no significant change in IGF-I levels, and was less effective than multiple daily doses. An earlier study (Corpas et al., 1992, JCEM) found that twice-daily GHRH (1-29) did reverse age-related declines in GH and IGF-I in older men. The honest summary: sermorelin reliably nudges GH, but durable outcome data for the modern anti-aging use case is limited.

Ipamorelin's human evidence is the thinnest of the three. Its well-characterized property — selectivity for GH release without cortisol or prolactin elevation — comes from preclinical rat and swine studies, not human outcome trials. There is no Phase 3 ipamorelin program comparable to tesamorelin's. This does not mean ipamorelin is ineffective; it means the claims attached to it rest on mechanism and clinical experience rather than randomized human data. This gap between demand and evidence is one academic specialists have flagged: Eileen Kennedy, a peptide-therapeutics chemist at the UNC Eshelman School of Pharmacy quoted in 2026 reporting on the FDA reclassification, has emphasized that the human trial evidence behind many of the most popular grey-market peptides remains thin.

Which has the fewest side effects?

Ipamorelin is generally considered the most selective of the three, which is its central safety advantage. It stimulates GH with minimal effect on cortisol or prolactin, unlike older secretagogues such as GHRP-6, which raise both. Sermorelin and tesamorelin, as GHRH analogs, also avoid major off-target hormone shifts but can cause injection-site reactions; tesamorelin trials additionally reported transient hyperglycemia early in treatment. Because all three stimulate the body's own GH rather than supplying it directly, somatostatin feedback stays intact, making supraphysiological GH levels harder to reach than with injected human growth hormone (HGH).

For ipamorelin, the most-cited safety point is what it does not do. In the preclinical work by Raun and colleagues, ipamorelin produced no rise in ACTH or cortisol even at doses far above the GH-releasing threshold — the property that distinguishes it from the older ghrelin mimetics GHRP-2 and GHRP-6, which a separate GHRP-2 vs GHRP-6 vs ipamorelin comparison covers in depth. Reported effects in practice are typically mild: injection-site irritation, occasional headache, or transient water retention. Human safety data, however, remains limited.

Tesamorelin has the most thoroughly documented adverse-event profile because it went through controlled trials. Across Phase 3 studies, the more common events versus placebo were injection-site reactions (erythema, pruritus), arthralgia, myalgia, peripheral edema, and paresthesia. There is a risk of mild hyperglycemia, particularly in the first weeks of treatment, though glucose generally returns toward baseline over several months and the trials did not show clinically significant changes in liver or kidney function. Sermorelin's reported effects are similarly mild — injection-site reactions, occasional flushing, headache, or lightheadedness.

One shared safety feature matters across all three: because they trigger endogenous GH within the body's own feedback loop, the risk of the acromegaly-type effects associated with high-dose exogenous HGH is lower. This is a genuine mechanistic advantage, but it is not the same as "risk-free." IGF-1 is the marker clinicians monitor on any of these peptides, and supervision matters — which is why a physician's involvement, rather than self-experimentation, is the safer path.

Which should you choose for your goal? (and can you stack them?)

Goal determines the best fit, because the three peptides were effectively built for different jobs. Tesamorelin is the most clinically validated option for visceral abdominal fat, with Phase 3 trial support. Sermorelin suits broad, gradual GH support — sleep, recovery, and body composition — and has the longest human-use history. Ipamorelin, prized for its selectivity, targets recovery and lean-mass goals and is most often stacked with a GHRH analog rather than used alone. For many users the practical decision is which combination to run, not which single peptide "wins."

If your specific concern is stubborn visceral fat — the deep abdominal fat associated with metabolic risk — tesamorelin is the only one of the three with direct human trial evidence for that outcome. The tesamorelin dosage calculator can help model a per-injection dose, though access and cost (covered below) are real constraints. If your goals are broader and gentler — better sleep, recovery, and a gradual lift in GH/IGF-1 — sermorelin's biomimetic, pulsatile action is a reasonable fit and the most affordable approved-history option. Ipamorelin's role is usually as the GHS half of a stack: it adds a ghrelin-receptor signal on top of a GHRH analog's signal.

Can you stack sermorelin and ipamorelin?

Yes — sermorelin and ipamorelin act on different receptors, so they can be combined, and many protocols do exactly that to amplify the GH pulse while keeping side effects low. The GHRH analog primes the somatotrophs while ipamorelin's ghrelin-receptor signal increases pulse amplitude, and because somatostatin feedback remains intact, the combined effect stays within physiological bounds. Human outcome data for these stacks is limited, however, so this should be done under medical supervision with IGF-1 monitoring.

The most common stack in practice pairs ipamorelin with CJC-1295 rather than sermorelin, because CJC-1295 (without DAC) is a longer-acting GHRH analog that aligns well with ipamorelin's window. The CJC-1295 and ipamorelin dosing calculator and the CJC-1295 and ipamorelin stack protocol guide cover the timing and reconstitution math; the broader peptide stacking guide explains why receptor-complementary pairs work and why stacking two ghrelin mimetics (for example, ipamorelin with GHRP-6) generally does not.

What's the legal and regulatory status of each?

The three occupy three different regulatory tiers — a distinction frequently blurred in marketing copy, and the cleanest way to understand your access options. Tesamorelin is FDA-approved (Egrifta, 2010; reformulated as Egrifta SV, 2019) for HIV-associated lipodystrophy, the only growth-hormone-releasing peptide with active FDA approval. Sermorelin was FDA-approved (Geref, 1997) and withdrawn in 2008 for commercial — not safety — reasons; it remains legally compounded through 503A and 503B pharmacies. Ipamorelin was never approved and is sold largely as research-use-only material, though it came off the FDA's Category 2 restricted list in April 2026. All three are prohibited in sport under WADA's section S2. (Regulatory status is moving quickly in 2026 — verify the current position before relying on it.)

Tesamorelin's approval gives it the strongest regulatory standing but the narrowest legal indication. It is approved only for reducing excess abdominal fat in HIV-positive adults with lipodystrophy; prescribing it for general obesity, metabolic syndrome, or anti-aging is off-label. It is sold as branded Egrifta and is not widely available through compounding pharmacies, both because the branded product exists and because the molecule is complex to compound.

Sermorelin holds a unique middle position. Its prior FDA approval — and the FDA's formal 2013 determination that Geref was withdrawn for commercial rather than safety or effectiveness reasons — gives compounding pharmacies stronger legal footing to prepare it than they have for never-approved peptides. It was not on the 2023 Category 2 list. In practice, sermorelin is widely compounded under 503A/503B for off-label adult use under a prescription, though it carries no active FDA approval as a finished drug.

Ipamorelin's status changed in 2026 and deserves a careful read, because three different things are routinely confused. In late 2023, the FDA placed 19 peptides — ipamorelin among them — on its Category 2 "do not compound" list of bulk drug substances. Following the February 27, 2026 announcement by HHS Secretary Robert F. Kennedy Jr., roughly a dozen of those peptides, including ipamorelin and CJC-1295, were removed from Category 2 effective April 23, 2026. But coming off Category 2 is not the same as being placed back on the compounding-eligible list, and neither is the same as FDA approval. "Category 1," "FDA-approved," and "research-use-only gray market" are three distinct statuses — a peptide can be compoundable under a prescription, legally sold only for laboratory research, and not FDA-approved, all at once. Most ipamorelin bought online still falls in the unregulated research-chemical category. A separate Pharmacy Compounding Advisory Committee review on July 23–24, 2026 covers a different set of seven peptides (not these three). For sport, the WADA Prohibited List bans GHRH analogs and GH secretagogues under section S2, so all three are prohibited for competing athletes.

How do you verify the ipamorelin, sermorelin, or tesamorelin you're buying is real?

Most ipamorelin and sermorelin sold online is unregulated research material, so verification matters more than any brand claim. Demand a recent third-party certificate of analysis (CoA) showing HPLC purity — ideally 98% or higher — for the specific compound, plus mass-spectrometry (MS) identity confirmation. HPLC measures purity but cannot, on its own, prove the vial contains the peptide on the label rather than a cheaper, mislabeled secretagogue. Cross-check the shop and the compound against independent lab-test data before ordering, and treat a missing or unverifiable CoA as a red flag. This is the question the conflicted "comparison" sites — most of which prescribe one of these compounds and won't offer the others — tend to skip.

The MS point is not a technicality for this particular comparison. The three peptides have very different molecular weights, and several adjacent GH secretagogues (GHRP-2, GHRP-6, hexarelin) are cheaper to synthesize. An HPLC chromatogram can show 99% purity while the 99% is the wrong molecule. Only mass spectrometry confirms identity by molecular weight — which is why a complete CoA pairs both. The guides on HPLC purity testing and mass spectrometry for peptide identity explain how to read each on a CoA.

Independent platform data is useful here precisely because Peptigrity does not sell peptides. Across the platform's independent lab-test database — currently 8,832 HPLC purity tests across 365 tracked shops (verified June 2026) — the three compounds show a telling pattern. Ipamorelin has accumulated 304 independent HPLC tests at a 99.7% average purity, tesamorelin 338 tests at 99.4%, and sermorelin 151 tests at 98.7% (verified June 2026). Two things stand out: ipamorelin — the never-approved, gray-market option — is the most-tested of the three by buyers, double sermorelin's volume, concretely confirming the evidence-versus-popularity inversion; and sermorelin's average purity is the lowest of the three, a real, buyer-relevant signal. These averages reflect samples submitted for testing, which skews toward shops confident in their product, so treat them as directional rather than a guarantee for any single vial.

For compound-specific sourcing checks, the where to buy ipamorelin guide and the where to buy sermorelin guide walk through the purity and identity verification steps for each. Tesamorelin is a different sourcing case: because the FDA-approved branded product exists, the most legitimate route is a prescription rather than research-grade material.

Frequently Asked Questions

Can you take sermorelin and ipamorelin together?

Yes. Sermorelin (a GHRH analog) and ipamorelin (a ghrelin mimetic) act on different receptors, so combining them produces a larger, synergistic GH pulse than either alone while keeping side effects low. Many protocols pair a GHRH analog with ipamorelin for this reason, though the most common partner is CJC-1295 rather than sermorelin. Human outcome data for these stacks is limited, so use them under medical supervision with IGF-1 monitoring.

Which is best for fat loss — ipamorelin, sermorelin, or tesamorelin?

Tesamorelin is the most clinically validated for fat loss, specifically visceral abdominal fat, with Phase 3 trials showing roughly 15% visceral-fat reduction. Ipamorelin's selectivity (no cortisol rise) may support fat-loss goals indirectly, since elevated cortisol works against fat loss. Sermorelin is the least fat-specific of the three. For overall weight loss rather than visceral fat specifically, GLP-1 medications produce substantially greater reductions than any of these GH peptides.

Is sermorelin or ipamorelin FDA-approved?

No. Only tesamorelin holds active FDA approval, as Egrifta, for HIV-associated lipodystrophy. Sermorelin was FDA-approved as Geref in 1997 but the brand was withdrawn in 2008 for commercial reasons; it is now legally compounded under prescription but carries no active approval. Ipamorelin has never been FDA-approved and is sold largely as research-use-only material, though it came off the FDA's Category 2 restricted list in April 2026.

How long does it take to see results?

Sleep and recovery changes are often reported within the first one to two weeks, while body-composition changes — leaner mass, reduced fat — typically take roughly three to six months, since they depend on a gradual rise in IGF-1 as the liver responds to increased GH. These timelines come from clinical experience and tesamorelin's trial data rather than from randomized studies of every compound, so individual responses vary with dose, age, and baseline GH status.

Why is tesamorelin so much more expensive than sermorelin or ipamorelin?

Tesamorelin is a branded, FDA-approved drug (Egrifta) sold through specialty pharmacies, which puts its monthly cost far above the alternatives. Sermorelin is compounded under 503A/503B pharmacy law at a much lower cost, and ipamorelin sold as research-grade material is cheaper still. The price ladder mirrors the regulatory tiers: approved branded drug, compounded former-drug, and unregulated research chemical, in descending order of both cost and oversight.

Are GH secretagogues safer than HGH injections?

They carry a different risk profile. Because ipamorelin, sermorelin, and tesamorelin stimulate the body's own GH within an intact somatostatin feedback loop, it is harder to reach the supraphysiological GH levels — and the associated acromegaly-type risks — that can occur with high-dose exogenous HGH. That feedback-limited mechanism is a genuine advantage, but these peptides are not risk-free, remain non-approved or off-label for most uses, and still warrant IGF-1 monitoring and medical supervision.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.